Sanja Dragnic

Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years

K. Klein, Petra Aldridge, Marcela Vargas Trujillo, 2021, Journal of pediatric endocrinology & metabolism : JPEM.

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer

W. White, L. Klotz, S. van Komen, 2022, Société Internationale d’Urologie Journal.

Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate

A. Soliman, K. Klein, P. Bacher, 2018, Journal of pediatric endocrinology & metabolism : JPEM.

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies

A. Soliman, M. Gittelman, L. Karsh, 2016, Research and reports in urology.

Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty

P. Backeljauw, K. Klein, S. van Komen, 2022, Journal of pediatric endocrinology & metabolism : JPEM.

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study

N. Mauras, K. Klein, Mayra Ballina, 2023, Journal of the Endocrine Society.

Research and Reports in Urology Dovepress Intramuscular Depot Formulations of Leuprolide Acetate Suppress Testosterone Levels below a 20 Ng/dl Threshold: a Retrospective Analysis of Two Phase Iii Studies

A. Soliman, M. Gittelman, L. Karsh, 2022 .